Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Apremilast Modified-Release Formulations
NCT02236988Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis and psoriatic arthritis (PsA) (4 arms), sponsored by Amgen. Primary endpoints: Observed Maximum Plasma Concentration at 72 hours, Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point at 72 hours and 6 more. Started Jan 2014; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02236988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236988.